

ADT medications with abiraterone/Zytiga or ADT medications with docetaxel/Taxotere chemotherapy – is one better than the other for men diagnosed with advanced, high grade, metastatic prostate cancer?

Either procedure is reasonable, but abiraterone with ADT medications is unlikely to have as significant side effects as chemotherapy/docetaxel with ADT medications.

In the paper below titled “Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis” and with the following objective: “To perform a systematic review and network meta-analysis of randomized clinical trials, indirectly evaluating overall survival (OS) for men treated with abiraterone acetate plus prednisone/prednisolone with ADT (Abi-ADT) versus docetaxel with ADT (Doce-ADT) in hormone-naïve high-risk and metastatic PCa.” The researchers/authors concluded that there was no statistical significant difference in overall survival between patients treated with abiraterone(Zytiga) and ADT medications and those treated with docetaxel/Taxotere and ADT medications. They also concluded that from another analysis there was a high likelihood that abiraterone/Zytiga with ADT medications was the preferred procedure.

[https://www.europeanurology.com/article/S0302-2838\(17\)30849-7/pdf](https://www.europeanurology.com/article/S0302-2838(17)30849-7/pdf)